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Introduction: Resistin increases during several inflammatory diseases and after intracerebral bleeding or head
trauma. Resistin activates the endothelium and may initiate an inflammatory response. No data are available on
resistin in brain dead donors (DBD) that regularly manifest a pronounced inflammatory state.
Methods: We analyzed plasma resistin in 63 DBDs and correlated results with donor variables and the postoperative
course following kidney transplantation using organs from these donors. Endocan and monocyte chemotactic protein
(MCP)-1 were also studied. Twenty-six live kidney donors (LD) and the corresponding kidney transplantations were used
as controls.
Results: DBDs had higher resistin (median/range 30.75 ng/ml, 5.41–173.6) than LD (7.71 ng/ml, 2.41–15.74, p < 0.0001).
Resistin in DBD correlated with delayed graft function (DGF) in the kidney recipients (r = 0.321, p < 0.01); receiver
operating characteristic curve revealed an area under the curve of 0.765 (95% confidence interval [CI] 0.648–0.881, p <
0.01) and a cut-off value for resistin of 25 ng/ml; MCP-1 and endocan were higher in DBDs (p < 0.0001) but did not
correlate with DGF or acute rejection. No relationship was found between the studied molecules and the postoperative
course of LD kidney transplants.
Conclusions: High resistin levels in the DBD before organ retrieval are associated with DGF after kidney transplantation.
The resistin increase seems related to the inflammatory state after brain death but not to the cause of death.Introduction
Brain death triggers a complex cascade of molecular
and cellular events including the release of various pro-
inflammatory mediators and leading to a pronounced
inflammatory state. The triggering stimulus of this phe-
nomenon remains unknown, but it eventually results in
endothelial and complement activation, massive cytokine
release, hemodynamic impairment and ultimately an
immunologically activated organ before transplantation
[1-4]. These changes increase the susceptibility for both
ischemia-reperfusion injury as well as rejection, and may
provide an explanation for the inferior results following* Correspondence: mihai.oltean@surgery.gu.se
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reproduction in any medium, provided the ortransplantation of organs from deceased donors as com-
pared with living donors [5].
Resistin has been initially described as an adipokine re-
lated to the insulin resistance in obese mice. In humans,
the expression pattern of resistin is different [6] and hu-
man resistin, synthesized predominantly by mononuclear
cells, has features similar to classical pro-inflammatory
cytokines playing a role in inflammation and immunity
[7,8]. The recent experimental and clinical evidence has
revealed a possible role of resistin in diverse pathological
settings such as atherosclerosis [9], rheumatic diseases
[10], cancer [11] and several other diseases [12-14]. In-
creased resistin levels have been reported during these
inflammatory conditions. It has been demonstrated that
pro-inflammatory cytokines can induce strong upreg-
ulation of resistin in peripheral blood mononuclear cells
[8,15] and in turn, resistin itself can promote inflamma-
tion through induction of a cytokine cascade [8,16]. The
systemic resistin increase seems to be related with theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion [13,14,17,18]. To date, very little is known about the
role of resistin after organ transplantation and there are no
published data available on resistin in organ donors.
Resistin is able to promote the endothelial cell activation
and mount a robust pro-inflammatory response [19]. Thus,
resistin may represent an injury marker as well as a pro-
inflammatory signal, which contributes to the inflam-
matory cascade after brain death. Other established
markers of endothelial activation and injury include several
soluble cell adhesion molecules, chemokines or other
endothelium-derived biomolecules (i.e., von Willebrand fac-
tor, glycoproteins, proteoglycans). Endocan is a proteogly-
can expressed by the endothelial cells that binds to human
leukocytes via the integrin leukocyte function-associated
antigen (LFA)-1 and can also be detected free in the blood
[20]. Inflammatory cytokines induce an up-regulation of
endocan messenger RNA and the release of the molecule
by the endothelium [20]. Endocan has recently been sug-
gested as a novel endothelial dysfunction marker with a
higher discriminative value for predicting septic shock and
death than the von Willebrand factor [20].
In this study we analyzed the circulating levels of
resistin in brain dead organ donors and in healthy living
donors at the time of organ procurement and studied its
relationship with two markers of endothelial activation
such as endocan, and monocyte chemotactic protein
(MCP-1) as well as the early post-transplant course.
Materials and methods
Patients and samples
Plasma samples were obtained from 63 deceased brain
dead (DBD) multiorgan donors from our procurement
area between August 2006 and March 2012. The donors
(or next of kin) previously consented for blood/tissue
donation for the purpose of medical research. Individ-
uals donating a kidney for transplantation i.e. living do-
nors (LD) at our unit served as healthy controls (n = 26).
The study was approved by the Ethical Committee of
Gothenburg University and consent was obtained from
all individuals.
Blood was drawn on EDTA-tubes from DBD donors
just prior to the organ recovery procedure. Following
centrifugation plasma was recovered, aliquoted and stored
at −80°C until analysis. Donor information regarding
age, gender, cause of death (COD), steroid pretreatment,
donors’ last creatinine, C-reactive protein and body mass
index (BMI) were retrieved. Plasma samples were also
obtained from healthy kidney donors and prepared as
above.
The early outcome after kidney transplantation
The early behavior of the kidneys retrieved from the
group of above described donors and transplanted inadult recipients at our center was followed. Five kidneys
were discarded before transplantation due to underlying
pathology (cysts, sclerosis). The kidneys shipped to other
Nordic transplant centers according to Scandiatransplant
exchange rules (n = 20), those transplanted together with
the liver (n = 9), or early technical failure (n = 1) were ex-
cluded from the analysis.
The medical records of the remaining 91 kidney graft
recipients were reviewed and information retrieved re-
garding cold ischemia time, recipient demographics,
graft function (creatinine), need for hemodialysis during
the first week after transplantation and occurrence of re-
jection during the first month. Day of surgery (release
of vascular clamps) was considered day 0. All kidneys
underwent static cold preservation in either University
of Wisconsin or histidine-tryptophane-ketoglutarate so-
lution. Kidneys from living donors were transplanted
within an hour from donor nephrectomy. Recipient im-
munosuppression was based on antibody induction ther-
apy (basiliximab or rituximab), calcineurin inhibitors,
mycophenolate mofetil and steroids.
The primary endpoint of the study was delayed graft
function (DGF), defined as requirement for hemodialysis
during the first week after transplantation. A secondary
endpoint was slow graft function (SGF) not requiring
dialysis, defined by a decrease in recipient serum cre-
atinine <30% from posttransplant day 1 to day 2 [21,22].
Creatinine reduction rate at day 2 (CRR2) was calculated
using the formula:
CRR2 (%): (Creatinine Day 1-Creatinine Day 2) * 100/
Creatinine Day 1.
Measurement of resistin, MCP-1 and endocan
Resistin was measured using a colorimetric sandwich
ELISA kit (DRSN00); MCP-1 was measured using a Duo
Set ELISA development kit (both from RND Systems,
Minneapolis, MN) following manufacturer’s instructions.
The lower detection limits were 0.16 ng/ml for resistin
and 15.62 pg/ml for MCP-1.
Endocan is a proteoglycan expressed only by the endo-
thelium, constitutively present on several vascular beds
including the glomerular and peritubular capillaries [23].
Endocan has been used as surrogate marker of endo-
thelial injury and activation and measured in the plasma
of deceased and living organ donors using a Human
endocan/ESM-1 DIY ELISA Kit (LIK-1101, Lunginnov,
Lille, France). The lower detection limit of the assay was
0,16 ng/ml.
Statistical analyses
Following the analysis of data distribution, Student’s
t-test and analysis of variance were used to calculate sam-
ples with normal distribution, whereas the Kruskal-Wallis
test and Mann–Whitney U test were used for the analysis
Table 1 Characteristics of the deceased brain-dead donors
and corresponding kidney recipients
Donors (n = 63) n (%)
Mean age, years (± SD) 51.6 (± 15.6)
Male 36 (57.2%)
Cause of death, n (%)
Cerebrovascular accident 45 (71.4%)
Traumatic brain injury 10 (15.8%)
Hypoxic brain damage 6 (9.6%)
Other 2 (3.2%)
Mean ICU days (± SD) 2,28 (± 2)
Inotropes 50 (79.3%)
Steroid pretreatment 38 (60%)
History of hypertension 18 (28.57%)
Mean BMI (± SD) 25.17 (± 4.66)
Mean plasma creatinine, μmol/L (± SD) 82.82 (± 42.78)
Mean eGFR, mL/min (± SD) 96.15 (± 43.35)
ECD 26 (41.26%)
Recipients (n = 91)
Mean age, years (± SD) 52.3 (12.44%)
Male, n (%) 56 (61.53%)
Polycystic disease 14 (15.3%)
Glomerulonephritis 39 (42.9%)
Diabetes mellitus 18 (19.9%)
Other 20 (21.9%)
First transplantation 67 (73.6%)
Retransplantation 24 (26.7%)
Antigen mismatches-A, B and DR (mean ± SD) 3,7 ± 1,3
Mean cold ischemia time, min (± SD) 802 (± 295.3)
SGF Slow graft function 73 (80,2%)
Delayed graft function 13 (14.3%)
Acute rejection during the first month 6 (6.6%)
Abbreviations: eGFR estimated glomerular filtration rate using the modification
of diet in renal disease (MDRD) equation for glomerular filtration rate in the 61
adult donors and the Schwartz equation in two donors under 18 years of age,
SD standard deviation, ECD extended criteria donors include any donor over
60 years old and donors 50–59 years old with at least two of the following:
terminal creatinine >1.5 mg/dL (114 μmol/ml), history of hypertension, or
death by cerebrovascular accident, DGF delayed graft function, SGF Slow graft
function, < 30% creatinine reduction rate at day 2.
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for analyses of contingency tables. The parametric correla-
tions were assessed using the Pearson correlation coeffi-
cient, and the nonparametric correlations were assessed
using the Spearman correlation coefficient. Receiver oper-
ating characteristic curve (ROC) analysis was performed to
assess the potential of resistin to predict DGF. Data are
expressed as median and range, unless otherwise stated. A
p-value < 0.05 was considered significant.
Results
Characteristics of donors and recipients
Table 1 summarizes donor (n = 63) and recipient (n = 91)
characteristics in the group of DBD kidney transplanta-
tions, while Table 2 shows the details of the living donor
(LD) kidney transplantations (n = 26).
After transplantation, delayed graft failure (DGF) oc-
curred in 13 (14.28%) of DBD kidney recipients, whereas
none of the LD kidney recipients developed DGF. Slow
graft function (SGF) was observed in 73 (80.2 %) of DBD
kidney recipients and in 10 (38.4%) recipients of LD.
Donor resistin and the post-transplant course
Resistin levels were significantly higher in the DBD and
had a median value of 30.75 ng/ml (5.41–173.6) com-
pared with a median of 7.71 ng/ml (2.41–15.74) the in
LD (p < 0.0001) (Figure 1A). Resistin concentration was
not influenced by the cause of death (Table 3) or the donor
body mass index (BMI). Steroid pretreated donors had
resistin levels not significantly different from untreated
DBDs.
When referring to DGF (need for hemodialysis during
the first posttransplant week), resistin was signifi-
cantly increased in the DBD donors of kidneys that
required dialysis compared with the donors of kidneys
not requiring dialysis: 41.87 (26.47–173.6) ng/ml vs.27.24
(5.41–149.3) ng/ml, p < 0.01. Resistin levels in the donor
correlated moderately with recipients’ need for dialysis dur-
ing the first week after transplantation (r = 0.321, p < 0.01).
ROC curve analysis for resistin differentiating between
recipients requiring HD (n = 13) and those not requiring
(n = 78) hemodialysis gave an area under the curve (AUC)
of 0.765 (95% confidence interval 0.648–0.881, p < 0.01)
(Figure 2). The cutoff value for resistin in predicting DGF
as revealed by the ROC curve was 25.
The association found by Fisher’s exact test between
the plasma resistin levels above 25 mg/ml in DBDs and
the risk of DGF is shown by an OR of 24,4 (95% CI 1,4–
425, p < 0.001). The calculated positive predictive value
for concentrations above 25 ng/ml was 0.241 while the
negative predictive value was 1.
While grouping the donors according to the resistin
levels, donor age did not differ between (51,5 ± 14 vs.
51,5 ± 16 years, p = 0.7). Donors with resistin less than25 ng/ml had lower last creatinine (66,9 ± 24 vs. 95,3 ±
47, p < 0.01) and a higher estimated GFR (112 ± 40 vs.
85 ± 42 ml/min/1.73m2, p < 0,01) than the donors with
resistin above 25 ng/ml. Vasoactive support has been
used in 66% and 41% of the donors with low (<25 ng/ml)
and high resistin (>25 ng/ml), respectively (p-ns.).
The average creatinine between days two and four
was significantly higher in recipients of kidneys from
donors with resistin >25 ng/ml (Figure 3). The difference
disappeared by day five possibly due to the initiation of
Table 2 The living donor kidney transplantations
Living donors (n = 26)
Mean age, years (± SD) 48.2 (± 13.7)
Male 8 (30.7%)
Mean body mass index 25.52 (± 4.66)
Mean plasma creatinine, μmol/L (± SD) 82.82 (± 42,78)
Mean eGFR, mL/min (± SD) 116 (± 34.8)
Recipients (n = 26)
Mean age, years (± SD) 45 (±12,44)
Male, n (%) 18 (69.2%)
Polycystic disease 3 (11.5%)
Glomerulonephritis 10 (42.4%)
Diabetes mellitus 4 (15.4%)
Other 9 (30.7%)
First transplantation 22 (84.6%)
Retransplantation 4 (15.4%)
Antigen mismatches-A, B and DR (mean ± SD) 2,8 ± 1,8
Delayed graft function 0
Acute rejection during the first month 8 (30.7%)
Characteristics of the living kidney donors and kidney recipients. Donor GFR
has been measured directly using either Cr-EDTA or Iohexol clearance.
Table 3 Median (range) plasma resistin, MCP-1 and
endocan concentrations in the brain dead donors
according to the cause of death
Resistin (ng/ml) MCP-1 (pg/ml) Endocan (ng/ml)
Major vascular
accident (n = 45)
28.7 (5.41–157) 121 (0–3723) 2.1 (0.654–7.87)
Trauma (n = 10) 34.3 (12.6–54.6) 122 (1.13–1800) 2.84 (1.13–3.92)
Hypoxia (n = 6) 34.3 (16.6–174) 190 (0–2675) 2.68 (1.17–12.4)
Other (n = 2) 71.73 (59.46–84) 275.7 (52.5–490) 1.56 (1.13–1.99)
MVA major vascular accident.
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inadequate graft function.
Further correlations between resistin and other donor-
related variables and post-transplant events are presented
in Table 4.
Donor endothelial activation and the post-transplant course
The median MCP-1 level in the DBD was 1118 pg/ml
(0.4–6624) whereas the median MCP-1 level in LD was
significantly lower: 20.21 pg/ml (0–72.47) (p < 0.0001)
(Figure 1B). Steroid pretreated donors had significantly
lower MCP-1 concentrations: 44.93 pg/ml (0–3723) vs.
506.8 pg/ml (14–2675) (p < 0.0001).Figure 1 The enzyme-linked immunosorbent assay (ELISA) results in t
living donors (LD, open box). DBDs had higher plasma concentrations oEndocan levels were found significantly increased in
DBD compared with LD: 2.14 ng/ml (0.65–12.36) vs.
1.12 ng/ml (0.41–6.62) (p < 0.0001) (Figure 1C). Donor
COD or steroid pretreatment did not influence endocan
concentrations. Both MCP-1 and endocan levels corre-
lated moderately with resistin concentrations (Table 4).
Discussion
Brain death induces an intense pro-inflammatory state
through several, incompletely known mechanisms. This
increases graft susceptibility to ischemia-reperfusion in-
jury but it may also cause direct injury to various trans-
plantable organs, thus explaining the inferior results
after transplantation of organs from deceased brain dead
donors [3,5,24]. In the present study we found signifi-
cantly higher concentrations of resistin in brain dead
organ donors and report for the first time an association
between increased resistin levels and the development of
DGF in the early posttransplant course.
The endothelium is a prime site of the brain death-
induced organ injury [25]. Endothelial cells are resistin-
sensitive cells, responding to resistin with up-regulation of
vascular cell adhesion molecules and MCP-1 [19]. Previous
studies have shown sizeable MCP-1 increase in brain dead
donors and identified elevated donor MCP-1 as predictive
for graft related complications after simultaneous pancreas-he plasma of brain dead organ donors (DBD, grey box) and
f resistin (A), MCP-1 (B) and endocan (C) as compared with LD.
Table 4 Correlation matrix (Spearman’s rank) for several
inflammatory biomarkers and renal function in the donor
and post-transplantation events with serum resistin levels
DBD LD
Markers of inflammation in the donor
CRP 0,246 (0,062) -
Endocan 0,394 (0,001) −0.115 (0.575)
MCP-1 0,353 (0,005) −0.191 (0.35)
Renal function in the donor
Last Creatinine 0,286 (0,025) -
eGRF −0,351 (0,006) 0.055 (0.791)
Clinical events after transplantation
DGF 0.321 (0.002) 0
SGF 0.113 (0.287) 0.2 (0.327)
AR 0.133 (0.208) 0.1 (0.627)
The associations between resistin levels and inflammatory biomarkers, parameters
of renal function as well as post-transplantation events in the deceased brain-dead
(DBD) and living (LD) donors. Spearman’s correlation coefficients (p value)
are shown.
BMI-body mass index, LOS-length of stay, AR-acute rejection, DGF-delayed
graft function.
Figure 2 Receiver operating characteristic curve of resistin as
predictor of DGF. Area under the curve followed by SE and 95% CI
are shown.
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after lung transplantation has been related to unfavorable
postoperative course [27]. We found that endothelial acti-
vation and endothelial injury in DBD donors are reflected
by significantly increased MCP-1 and endocan levels. The
moderate correlation between MCP-1 and resistin suggests
that additional stimuli or mechanisms other that resistin
may have contributed to the MCP-1 release.
Recent studies point out resistin as a ligand for Toll-like
receptor 4 that mediates the pro-inflammatory effects of
resistin in human cells [28]. Resistin can induce dose-
dependent activation of mononuclear cells with intracellu-
lar signaling occurring through the NF-kappa B pathway,
the same pathway that controls transcriptional activation
and gene expression of major pro-inflammatory cytokines,
chemokines and endothelial adhesion molecules involvedFigure 3 The decrease in post-operative serum creatinine
concentrations during the first week in recipients of kidneys
from DBD donors with resistin <25 ng/ml (grey bars, n = 24),
resistin >25 ng/ml (black bars, n = 39) and living donors (white
bars, n = 26). * p < 0.05.in leukocyte adhesion and transmigration from blood ves-
sels to interstitium [12,19]. Similarly, our study found that
the early behavior of the kidney grafts depends on the con-
centrations of resistin in the donors. The distinct pattern
of creatinine fall between kidneys coming from donors
with low or high resistin may suggest that the difference is
due to different degrees of ischemia-reperfusion injury but
in the absence of biopsy findings this hypothesis remains
speculative.
The association between resistin and MCP-1 in the
brain dead organ donors seems to indicate a causative
relationship between these two and may suggest a role
for resistin in the initiation of the inflammatory response
after brain-death. Unlike MCP-1, resistin did not appear
influenced by the steroid pretreatment, suggesting either
a different mechanism (i.e., passive release instead of de-
novo synthesis) or a more upstream position in the in-
flammatory cascade that is not influenced by medication.
The effect of steroid treatment on resistin and endocan-
1 is more difficult to assess since our data come from only
one, rather late time-point. This hypothesis should be pref-
erably studied at several time points before and after the
intervention.
Increased resistin concentrations were reported after
head trauma or intracerebral bleeding [29-31]. Several
studies suggest that resistin levels are proportional with
the magnitude of injury and indicative for prognosis fol-
lowing ischemic or hemorrhagic stroke [29,31]. Interest-
ingly, resistin concentrations observed after head trauma
or intracerebral bleeding were similar with the concentra-
tions reported herein. It seems unlikely that resistin leaked
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some brain-dead individuals with severe brain infarction
had only modest increases in resistin levels. Moreover, the
missing cerebral circulation implies an absent venous
drainage of the brain tissue. Although the exact source of
resistin in DBD donors remains unclear, it is plausible that
dysregulation of neural and hormonal signals occurring
after donor brain death leads to the release of resistin from
activated immune cells.
Increased resistin levels have been reported in patients
with chronic renal disease and interesting relationships
between resistin concentration, glomerular filtration rate
and several biomarkers of inflammation have been iden-
tified [32,33]. Although the exact mechanisms are un-
clear, the study by Axelsson et al. [32] suggested that
hyper-resistinemia appears to be linked to inflammation
but not to obesity and insulin resistance. Comparable re-
sults were reported in a small cohort of patients with
IgA nephritis [34]. Interestingly, our study found a sta-
tistically significant (albeit clinically marginal) difference
in the renal function of donors with resistin above or
below the cut-off value identified herein. Whether this is
secondary to the inflammatory, brain death–induced
kidney injury or due to preexisting renal impairment re-
mains unclear. One interesting theory that arose from
those studies is that resistin secretion through the kid-
neys may be the major pathway of its elimination. The
inverse correlation between donor estimated GFR and
resistin, further supports the hypothesis that increased
resistin may be associated with renal damage.
Endocan is expressed only by the endothelium and
constitutively present on several vascular beds including
the glomerular and peritubular capillaries [23], although
a circulating endocan fraction can also be normally
detected. It has been suggested as a marker of endothe-
lial dysfunction and increased endocan levels have been
signaled in septic patients [20]. Limited information is
available in critically ill patients and there is no pub-
lished evidence on the role of endocan during aging or
kidney diseases. The increased endocan concentrations
in the brain dead donors and its correlation with MCP-1
may suggests that the increase in soluble endocan is part
of the inflammatory response, but it remains unclear if
this increase is indicative of organ injury. Further studies
in patients with specific diseases could shed more light
on the role of endocan as a marker of organ injury.
Donor age and the inotrope support are critical donor-
related variables that may influence kidney graft func-
tion, yet several more subtle donor parameters such as
the inflammatory milieu have been recognized to have
impact on the transplant outcome [34]. Currently, the
assessment of kidney function at the time of organ pro-
curement is based mainly on routine parameters such as
urine output or serum creatinine, although the later is arelatively insensitive marker of renal dysfunction and in-
creases only in the late phases of injury. Additional infor-
mation about donor and graft could assist in the initial
decision making such as organ allocation or choice of im-
munosuppression. Several molecular changes in the organ
donor have been suggested to correlate with early graft
function and post-transplant outcome but have not yet
been adopted into the clinical routine [22,35-38]. The sig-
nificant correlation between the pro-inflammatory resistin
and DGF and the cut-off value identified by our study as
well as its rapid and simple assessment may suggest a place
for resistin in a future panel of inflammation markers used
in the assessment of the organ donor as well as a param-
eter with prognostic value for the function of the renal
grafts.
Delayed graft function is unequivocally defined as the
requirement for dialysis during the first post-transplant
week, whereas slow graft function has several definitions
and consequently, varying frequency [22,39-41]. The rate
of DGF seen in our study is similar with that reported in
the literature. However, the rather high threshold of 30%
for creatinine reduction rate at day 2 we adopted could
have contributed to a higher frequency of SGF. On the
other hand, the high frequency could be attributable to
donor-related factors since almost half of the transplanted
kidneys came from extended criteria donors [42].
The present work is a single-center study and has the
inherent limitations of any small series. In an attempt to
ensure an overall good pre-transplant organ quality and
facilitate the post-transplant comparisons we chose to
include only multiorgan DBDs and this may have resulted
in a selection bias. Also, the relatively low number of do-
nors and kidney transplants prevented further in-depth
subgroup analyses. However, our single center study had
the advantage of managing both organ donors and trans-
plant recipients according to similar protocols and routines
throughout the study. Although non-consecutive, the do-
nors in our study mirror well the donors at our center with
respect to age, gender and cause of death.
The collection of data from only one time-point is an-
other limitation of the study. This prevented detailed
mechanistic studies but provided an identical, clinically
feasible time-point. We are currently conducting a pro-
spective study analyzing the time-course of resistin at
several time-points between the declaration of brain
death and organ retrieval.
Conclusions
This first report investigating resistin in brain-dead
organ donors indicates that high resistin levels in the
donor at organ retrieval are associated with delayed graft
function. The increase in resistin levels is not influenced
by the cause of death but rather reflects the inflamma-
tory state after brain death. Our observations need to be
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also include extended criteria donors, where any add-
itional information could provide key data regarding
organ allocation.
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